
AstraZeneca PLC
AZNHealthcare|Drug Manufacturers - General|GB
$186.43
-0.42 (-0.22%)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23
Clinical Trials (507)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07476859 Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome | Acute Coronary Syndromes (ACS), Iron Deficiencies | P4 | Recruiting | 538 | RCT, Open-label | Ferric Carboxymaltose Injection [Ferinject] |
| NCT07177417 Characterizing the Human Airway Immune Response to FluMist Vaccination | Healthy Young Adults, Influenza Vaccines | P4 | Recruiting | 30 | RCT, Open-label | FluMist, inactivated influenza vaccine |
| NCT07647328 A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer | ER-Positive HER2-Negative Breast Cancer | P3 | Recruiting | 150 | Open-label | Camizestrant, Ribociclib |
| NCT07430306 A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P3 | Recruiting | 245 | Open-label | Anifrolumab |
| NCT07000123 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | Cardiovascular Disease | P3 | Active | 3,103 | RCT, Double-blind | AZD0780, Placebo |
| NCT06904170 Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma | Hepatocellular Carcinoma | P2P3 | Recruiting | 196 | RCT, Open-label | Durvalumab Plus Tremelimumab, HAIC (GEMOX) |
| NCT03875235 Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) | Biliary Tract Neoplasms | P3 | Active | 810 | RCT, Double-blind | Durvalumab, Placebo |
| NCT07205822 A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | Breast Cancer | P3 | Recruiting | 100 | Open-label | Dato-DXd |
| NCT06952803 A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Prostate Cancer | P3 | Recruiting | 700 | RCT, Double-blind | Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT) |
| NCT07005128 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | P3 | Active | 350 | RCT, Open-label | Tarlatamab, Durvalumab, Carboplatin, Etoposide |
| NCT06989112 DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Endometrial Cancer | P3 | Recruiting | 600 | RCT, Open-label | Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel |
| NCT04924608 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | Neurofibromatosis 1, Plexiform Neurofibroma (PN) | P3 | Active | 145 | RCT, Double-blind | Selumetinib |
| NCT07662135 A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin | Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease | P3 | Recruiting | 900 | RCT, Double-blind | Elecoglipron, Placebo |
| NCT07761117 A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | P3 | Recruiting | 6,950 | RCT, Double-blind | Elecoglipron, Placebo |
| NCT07363642 Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab | Severe Asthma | P3 | Recruiting | 400 | Open-label | Tezepelumab |
| NCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | Non-small Cell Lung Cancer | P3 | Active | 25 | RCT, Single-blind | Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT |
| NCT03778957 A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma | Hepatocellular Carcinoma | P3 | Active | 724 | RCT, Double-blind | Durvalumab, Bevacizumab |
| NCT07775404 A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus | Obesity, Overweight | P3 | Recruiting | 351 | RCT, Double-blind | Elecoglipron, Placebo |
| NCT06350097 Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | P3 | Recruiting | 582 | RCT, Open-label | Osimertinib, Datopotamab Deruxtecan |
| NCT04191304 A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) | Hypereosinophilic Syndrome | P3 | Active | 134 | RCT, Double-blind | Benralizumab, Placebo |
| NCT05624450 Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | Viral Lung Infection and Acute Respiratory Failure | P3 | Recruiting | 3,527 | RCT, Double-blind | Tozorakimab, Placebo |
| NCT05374291 The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | Kidney Disease, Chronic, Renal Transplant Failure | P3 | Active | 1,750 | RCT, Double-blind | Dapagliflozin 10 mg/day (oral), Placebo |
| NCT07764978 Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | Newly Diagnosed Multiple Myeloma | P3 | Recruiting | 750 | RCT, Open-label | AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine |
| NCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer | Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer | P3 | Active | 1,246 | RCT, Open-label | Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine |
| NCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Lymphoma, Mantle Cell | P3 | Active | 635 | RCT, Double-blind | Acalabrutinib, Bendamustine, Rituximab, Placebo |
| NCT06112379 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | Breast Cancer | P3 | Active | 1,902 | RCT, Open-label | Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib |
| NCT07784725 A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus | Obesity or Overweight | P3 | Recruiting | 2,500 | RCT, Double-blind | Lenbelintide, Placebo |
| NCT04960709 Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin | Muscle Invasive Bladder Cancer | P3 | Active | 712 | RCT, Open-label | Durvalumab, Tremelimumab, Enfortumab Vedotin |
| NCT06467357 Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Biliary Tract Cancer | P3 | Recruiting | 620 | RCT, Open-label | Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig |
| NCT03668340 AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | Uterine Cancer | P2 | Active | 49 | Open-label | AZD1775 |
| NCT07285213 Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | Clostridioides Difficile Infection | P2 | Recruiting | 230 | RCT, Double-blind | AZD5148 |
| NCT07017179 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight | Obesity/Overweight | P2 | Active | 16 | RCT, Double-blind | AZD6234, Placebo, AZD9550, Plocebo, AZD6234 in combination with AZD9550, Placebo |
| NCT03899337 A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome | Richter Syndrome | P2 | Active | 72 | RCT, Open-label | Acalabrutinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Rituximab |
| NCT03932331 Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies | Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | P1P2 | Active | 105 | Open-label | Acalabrutinib |
| NCT05801029 A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations | Non-Small Cell Lung Cancer (NSCLC) | P2 | Active | 60 | Open-label | Osimertinib, Amivantamab |
| NCT06921928 Study for AZD4360 in Participants With Advanced Solid Tumours | Gastric Cancer, Gastroesophageal Junction Cancer | P1P2 | Active | 31 | Open-label | AZD4360 |
| NCT06749457 A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) | Staphylococcus Aureus | P1P2 | Active | 242 | RCT, Double-blind | AZD7760 |
| NCT06535607 Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors | Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) | P2 | Recruiting | 257 | RCT, Open-label | Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU |
| NCT05065554 ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | IgM MGUS, Waldenstrom Macroglobulinemia | P2 | Active | 12 | Open-label | Acalabrutinib, Rituximab |
| NCT07058519 A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC | Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) | P2 | Recruiting | 250 | Open-label | Osimertinib-based adaptive treatment, Osimertinib 80 MG |
| NCT04931654 A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | Carcinoma, Non-Small-Cell Lung, Gastric Cancer | P1P2 | Active | 136 | RCT, Open-label | AZD7789 |
| NCT03768570 Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | Bladder Cancer | P2 | Active | 82 | RCT, Open-label | Durvalumab |
| NCT06680596 Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy | Breast Cancer Metastatic, Breast Cancer Stage IV | P2 | Recruiting | 80 | Open-label | trastuzumab derxutecan |
| NCT07681596 A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | P1P2 | Recruiting | 101 | Open-label | AZD4045, Daratumumab, Aldesleukin |
| NCT06440993 Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma | Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA | P2 | Recruiting | 42 | Open-label | Gemcitabine, Cisplatin, Durvalumab |
| NCT03741426 WIRE - Novel Treatments in Renal Cell Cancer | Renal Cell Cancer | P2 | Recruiting | 134 | Open-label | Olaparib, Cediranib, Volrustomig, Rilvegostomig |
| NCT05982678 Basket Study for Oligo-metastatic Breast Cancer | HER2-positive Breast Cancer | P2 | Recruiting | 72 | Open-label | Trastuzumab deruxtecan |
| NCT07115043 A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | Melanoma, Non-small Cell Lung Cancer | P1P2 | Recruiting | 120 | Open-label | AZD6750, rilvegostomig |
| NCT06137118 AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | B-cell Acute Lymphoblastic Leukemia (B-ALL) | P1P2 | Recruiting | 255 | RCT, Open-label | Surovatamig |
| NCT06973564 JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration | Advanced Solid Tumors | P1P2 | Recruiting | 344 | Open-label | JAB-23E73, Cetuximab |
| NCT03704480 Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | P2 | Active | 106 | Open-label | Durvalumab, Tremelimumab |
| NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma, Biliary Tract Cancer | P2 | Active | 294 | Open-label | Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin |
| NCT04214288 A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer | Advanced ER-Positive HER2-Negative Breast Cancer | P2 | Active | 240 | RCT, Open-label | AZD9833, Fulvestrant |
| NCT07717840 A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) | RSV Respiratory Syncytial Virus | P1P2 | Active | 164 | RCT, Double-blind | AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2 |
| NCT05256641 Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | P1P2 | Recruiting | 24 | Open-label | Acalabrutinib |
| NCT07446855 Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours | Solid Tumours | P1P2 | Recruiting | 180 | RCT, Open-label | AZD4956, Saruparib |
| NCT07485452 Boosting Osimertinib Blood Brain Barrier Penetration | Non-Small Cell Lung Cancer | P2 | Recruiting | 7 | Open-label | Osimertinib & febuxostat |
| NCT02546661 Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | Muscle Invasive Bladder Cancer | P1 | Active | 117 | RCT, Open-label | AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib |
| NCT04556773 A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | Metastatic Breast Cancer | P1 | Active | 138 | Open-label | Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine |
| NCT06564623 Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) | Biliary Tract Cancers | P1 | Recruiting | 25 | Open-label | mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab |
| NCT07723833 A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | Healthy Participants | P1 | Recruiting | 152 | RCT, Open-label | Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B |
| NCT03819465 A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC | Metastatic Non-Small Cell Lung Cancer (NSCLC) | P1 | Active | 175 | RCT, Open-label | Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936 |
| NCT02264678 Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer | P1 | Active | 358 | Open-label | Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin |
| NCT07073547 A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | Multiple Myeloma | P1 | Recruiting | 40 | Open-label | AZD0120 |
| NCT03641755 Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | Breast Cancer | P1 | Active | 10 | Open-label | Sapacitabine, Olaparib |
| NCT06465810 Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis | Transthyretin Amyloidosis, ATTR-CM | Recruiting | 1,850 | — | Treatment of transthyretin (ATTR) amyloidosis in observational study setting | |
| NCT06252753 Observational Study Protocol: LIVER-R | Hepatobiliary Cancers | Recruiting | 4,000 | — | — | |
| NCT06981169 PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults | Asthma, Inflammation | Recruiting | 1,500 | — | — | |
| NCT07205666 The Eplontersen Pregnancy and Lactation Outcomes Study | Transthyretin Amyloidosis | Recruiting | 10 | — | — | |
| NCT06491862 RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil | Non-squamous Non-Small Cell Lung Cancer | Recruiting | 250 | — | — | |
| NCT06417801 Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling. | Metastatic Breast Cancer | Recruiting | 170 | — | — | |
| NCT07338942 Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations | ATTR-CM | N/A | Active | 4,000 | Open-label | — |
| NCT05103605 Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations | Non Small Cell Lung Cancer | Active | 274 | — | Osimertinib | |
| NCT07069829 Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo | Chronic Obstructive Pulmonary Disease | Recruiting | 1,400 | — | — | |
| NCT06336330 Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany | Heart Diseases, Cardiovascular Diseases | Active | 831 | — | — | |
| NCT06489964 Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies | Preventable Disease, Vaccine | N/A | Recruiting | 600 | RCT, Open-label | — |
| NCT06544629 Imjudo & Imfinzi PMS | Hepatocellular Carcinoma | Recruiting | 246 | — | — | |
| NCT07419555 Belgian Lung Function Study | Chronic Respiratory Diseases | Recruiting | 5,000 | — | — | |
| NCT06427876 Fasenra Pediatric Japan Post-Marketing Study(PMS) | Bronchial Asthma | Active | 40 | — | — | |
| NCT06472310 Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR) | Severe Asthma | Recruiting | 5,000 | — | — | |
| NCT03958136 Clinico-biological Data Collection Study of Metastatic Breast Cancer | Breast Cancer | N/A | Active | 289 | Open-label | Biomarkers blood, urine and microbiota samples |
| NCT07593196 HER2-positive Metastatic Breast Cancer in Kazakhstan | Metastatic Breast Cancer | Recruiting | 240 | — | — | |
| NCT02819882 A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) | Breast Neoplasms | Recruiting | 1,867 | — | — | |
| NCT05573893 PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan | Breast Neoplasms, Breast Cancer | Recruiting | 800 | — | — | |
| NCT07663409 The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP" | CRSwNP or CRSsNP Patients | Recruiting | 230 | — | — | |
| NCT00521365 Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder. | Bipolar Disorder, Bipolar Affective Psychosis | P4 | Completed | 88 | Open-label | Quetiapine 600mg |
| NCT00621153 Candesartan Effect in Second Stage Arterial Hypertension | Stage II Hypertension | P4 | Completed | 214 | RCT, Open-label | Candesartan Cilexetil, Hydrochlorothiazide, Candesartan Cilexetil |
| NCT01443845 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) | COPD, COPD Exacerbation | P4 | Completed | 2,354 | RCT, Double-blind | Roflumilast, Placebo |
| NCT02919345 Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery | Diabetes Mellitus, Type 2, Coronary Artery Disease | P4 | Completed | 98 | RCT, Open-label | Dapagliflozin 10 mg, Glibenclamide 5 mg |
| NCT00489853 Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD | Chronic Obstructive Pulmonary Disease | P4 | Completed | 137 | RCT, Double-blind | budesonide/formoterol Turbuhaler 320/9µg, formoterol Turbuhaler 9µg |
| NCT02429765 Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease | COPD | P4 | Completed | 40 | RCT, Double-blind | ACL/FOR, Placebo |
| NCT00631189 Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients | Type IIa and IIb Hypercholesterolaemia | P4 | Completed | 668 | RCT, Double-blind | Rosuvastatin, Pravastatin, Atorvastatin |
| NCT01787097 Effect of Symbicort ® on GR in Sputum in COPD | Chronic Obstructive Lung Disease | P4 | Completed | 31 | RCT, Open-label | Symbicort® total dose 400ug/12ug, Symbicort® total dose 800ug/24ug, Formoterol 24ug, BUD total dose 800ug |
| NCT00254241 Safety and Efficacy of Seroquel in First Episode Schizophrenia | Schizophrenia | P4 | Completed | 80 | RCT, Single-blind | Seroquel and Risperidone |
| NCT01006603 Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin | Type 2 Diabetes Mellitus | P4 | Completed | 957 | RCT, Double-blind | Saxagliptin, Glimepiride |
| NCT00234390 PreAsthmaControl (PAC) | Asthma | P4 | Completed | 400 | RCT, Double-blind | Pulmicort (budesonide) pMDI |
| NCT00237393 Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD) | PTSD | P4 | Completed | 80 | RCT, Double-blind | Quetiapine, Placebo |
| NCT00926393 Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression | Bipolar Depression | P4 | Completed | 139 | RCT, Double-blind | Quetiapine Immediate Release, Quetiapine Extended Release |
| NCT00295412 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients | Schizophrenia, Substance Use Disorders | P4 | Completed | — | Open-label | quetiapine (drug) |
| NCT00851461 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy | Spinobulbar Muscular Atrophy, Kennedy's Disease | P4 | Completed | 10 | RCT, Open-label | Goserelin |
| NCT02839889 Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) | Cancer, Constipation | P4 | Terminated | 12 | RCT, Double-blind | Naloxegol, Placebo |
| NCT00477581 A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P4 | Completed | 102 | RCT, Double-blind | exenatide, sitagliptin |
| NCT00272753 Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations | Asthma | P4 | Completed | 20 | RCT, Double-blind | budesonide/formoterol Turbuhaler, formoterol Turbuhaler, salbutamol |
| NCT00562081 The Virtual Asthma Clinic | Asthma | P4 | Terminated | 27 | RCT, Single-blind | — |
| NCT02585804 Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects | Focal Segmental Glomerulosclerosis | P4 | Completed | 10 | Open-label | Dapagliflozin |
| NCT02663713 A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction | Myocardial Infarction, Diabetes Mellitus | P4 | Completed | 20 | RCT, Single-blind | Ticagrelor, Clopidogrel |
| NCT01203917 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC | Caucasian Patients With EGFR Mutation Positive Advanced NSCLC | P4 | Completed | 1,060 | Open-label | Gefitinib |
| NCT00766350 Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia | Fibromyalgia | P4 | Completed | 90 | RCT, Open-label | amitriptyline, quetiapine |
| NCT06374043 Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. | Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria | P4 | Completed | 20 | RCT, Double-blind | Dapagliflozin 10mg Tab, Placebo |
| NCT02972476 Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial | Chronic Obstructive Pulmonary Disease | P4 | Completed | 158 | RCT, Open-label | Budesonide & formoterol fumarate and Aclidinium bromide, Fluticasone 500 & salmeterol and Aclidinium bromide, Fluticasone 250 & salmeterol and Aclidinium bromide, Aclidinium bromide & formoterol fumarate |
| NCT04078152 Durvalumab Long-Term Safety and Efficacy Study | Solid Tumor | P4 | Completed | 163 | Open-label | Durvalumab |
| NCT00870194 A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin | Type 2 Diabetes Mellitus | P4 | Completed | 255 | RCT, Double-blind | exenatide and sitagliptin, exenatide and placebo |
| NCT02518464 Ticagrelor Therapy for RefrACTORy Migraine Study | Migraine, Headache | P4 | Completed | 40 | Open-label | Ticagrelor 90 mg twice per day |
| NCT06590740 Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients. | Cough-Variant Asthma | P4 | Completed | 1,000 | Open-label | Budesonide-Formoterol treatment |
| NCT00318968 Nexium RESPONSE Trial | GERD | P4 | Completed | 1,000 | RCT, Double-blind | Esomeprazole |
| NCT02153489 A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | P4 | Completed | 30 | RCT, Double-blind | Aclidinium bromide, Placebo |
| NCT04219124 The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes | Type 2 Diabetes | P4 | Completed | 9 | RCT, Double-blind | IMP oral tablet, Placebo oral tablet |
| NCT00576316 Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia | Asthma | P4 | Completed | 201 | Open-label | Symbicort Turbuhaler 160/4.5 |
| NCT01826175 Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study | Acute Coronary Syndrome, Coronary Artery Disease | P4 | Withdrawn | — | RCT, Single-blind | Ticagrelor, Clopidogrel |
| NCT00954122 Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia | Schizophrenia | P4 | Completed | 35 | Open-label | Quetiapine XR (Seroquel XR) |
| NCT01242527 Epanova® for Lowering Very High Triglycerides | Severe Hypertriglyceridemia | P2P3 | Completed | 399 | RCT, Double-blind | placebo, omefas, omefas, omefas |
| NCT05062759 Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma | Moderate to Severe Asthma | P3 | Completed | 70 | RCT, Double-blind | Tezepelumab, Placebo |
| NCT03303066 Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | Anemia, Myelodysplastic Syndrome | P2P3 | Completed | 43 | RCT, Double-blind | FG-4592, Placebo |
| NCT02783573 A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia | Alzheimer's Disease | P3 | Terminated | 1,722 | RCT, Double-blind | Lanabecestat, Placebo |
| NCT00852631 Seroquel XR in Adults With Schizophrenia | Schizophrenia | P3 | Terminated | 28 | Open-label | Quetiapine fumarate (Seroquel) |
| NCT00640601 Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia | Schizophrenia | P3 | Completed | 331 | Open-label | Quetiapine Fumarate Extended- Release |
| NCT00642187 New Version Pulmicort Turbuhaler USA Adults | Asthma | P3 | Completed | 525 | RCT, Single-blind | budesonide, Placebo |
| NCT02174627 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis | Anemia | P3 | Completed | 2,781 | RCT, Double-blind | Roxadustat, Placebo |
| NCT00257205 CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy | Melanoma | P3 | Completed | 655 | RCT, Open-label | dacarbazine, CP-675,206, temozolomide |
| NCT00646529 Long-Term Safety of Symbicort in Asthmatic Children - SAPLING | Asthma | P3 | Completed | 175 | RCT, Open-label | budesonide/formoterol (Symbicort), budesonide (Pulmicort) |
| NCT02808819 A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist | Asthma | P3 | Completed | 447 | Open-label | Benralizumab, Benralizumab |
| NCT03473977 Benralizumab for Eosinophilic Gastritis (BEGS) | Eosinophilic Gastritis or Gastroenteritis | P2P3 | Completed | 26 | RCT, Double-blind | Benralizumab, Placebo |
| NCT00107107 Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P3 | Completed | 190 | Open-label | pramlintide acetate |
| NCT02104817 Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia | Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD) | P3 | Completed | 13,078 | RCT, Double-blind | Epanova® (omega-3 carboxylic acids), corn oil control |
| NCT02110303 DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury | Coronary Artery Disease | P2P3 | Completed | 220 | RCT, Double-blind | Ticagrelor, Placebo |
| NCT00359879 Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes | Type 2 Diabetes | P3 | Completed | 377 | RCT, Open-label | exenatide, exenatide |
| NCT00114686 Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder | Bipolar I Disorder, Alcohol Dependence | P3 | Completed | 350 | RCT, Double-blind | Quetiapine fumarate, lithium, divalproex |
| NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] | Acute Ischaemic Stroke, Transient Ischaemic Attack | P3 | Completed | 13,307 | RCT, Double-blind | ticagrelor, Acetylsalicylic acid (ASA) |
| NCT00888082 Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy | Breast Cancer, Ovarian Function | P3 | Withdrawn | 102 | RCT, Open-label | Goserelin acetate |
| NCT00683657 Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone | Type 2 Diabetes | P3 | Completed | 93 | RCT, Double-blind | Saxagliptin, Placebo |
| NCT02322775 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma | Asthma | P3 | Completed | 211 | RCT, Double-blind | Benralizumab, Placebo |
| NCT00654602 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety | Dyslipidaemia | P3 | Completed | 1,500 | Open-label | Rosuvastatin |
| NCT00241501 Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients | Gastroesophageal Reflux Disease (GERD) | P3 | Completed | 140 | RCT, Double-blind | Esomeprazole (Nexium) |
| NCT00163527 Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013) | Asthma | P3 | Completed | 2,054 | RCT, Double-blind | Roflumilast |
| NCT00206310 Crestor Versus Placebo in Subjects With Heart Failure | Heart Failure | P3 | Completed | 5,013 | RCT, Double-blind | CRESTOR |
| NCT03534453 Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy | P3 | Completed | 229 | Open-label | Olaparib 300mg tablets |
| NCT00884663 Candesartan Versus Propranolol for Migraine Prevention | Migraine Without Aura, Migraine With Aura | P2P3 | Completed | 72 | RCT, Double-blind | Candesartan, propranolol, placebo |
| NCT02701140 Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease | Myocardial Ischemia | P2P3 | Completed | 58 | RCT, Double-blind | — |
| NCT00784680 ATAC - Quality of Life Sub-Protocol | Quality of Life | P3 | Completed | 308 | RCT, Double-blind | Anastrozole, Tamoxifen |
| NCT00423475 Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer | Prostate Cancer | P3 | Completed | 743 | RCT, Open-label | goserelin acetate |
| NCT00660595 Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose | Schizophrenic Disorders | P3 | Terminated | 29 | RCT, Open-label | Quetiapine, Risperidone |
| NCT01256177 Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression | Bipolar Depression | P3 | Completed | 361 | RCT, Double-blind | Quetiapine Fumarate (SEROQUEL) Extended Release, Placebo |
| NCT02918071 Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home | Asthma | P3 | Completed | 121 | Open-label | Benralizumab |
| NCT00306540 Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder | Post-Traumatic Stress Disorder | P3 | Completed | 90 | RCT, Double-blind | Quetiapine Fumarate, quetiapine fumarate placebo |
| NCT00313313 A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas | Diabetes | P3 | Completed | 768 | RCT, Double-blind | Saxagliptin, Saxagliptin, Glyburide, Placebo, Glyburide, Metformin |
| NCT02875834 A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia | Hyperkalemia | P3 | Completed | 267 | RCT, Double-blind | Sodium Zirconium Cyclosilicate (ZS) 10g, Sodium Zirconium Cyclosilicate (ZS) 5g, Sodium Zirconium Cyclosilicate (ZS) 10g, Placebo |
| NCT00660907 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients | Type 2 Diabetes | P3 | Completed | 1,217 | RCT, Double-blind | dapagliflozin, glipizide, metformin hydrochloride |
| NCT01370538 Efficacy of Esomeprazole in Patients With Frequent Heartburn | Heartburn | P3 | Completed | 341 | RCT, Double-blind | Esomeprazole |
| NCT02446899 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus | Active Systemic Lupus Erythematosus | P3 | Completed | 373 | RCT, Double-blind | Anifrolumab, Placebo |
| NCT03470311 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies | Severe Prednisone Dependent Eosinophilic Asthma | P3 | Completed | 20 | Single-blind | Benralizumab, Placebo |
| NCT00034892 CAFE Comparison of Atypicals in First Episode of Psychosis | Schizophrenia, Psychotic Disorders | P3 | Completed | — | RCT, Double-blind | Olanzapine, risperidone |
| NCT03734029 Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Breast Cancer | P3 | Completed | 557 | RCT, Open-label | Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel |
| NCT02268214 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes | Type 1 Diabetes Mellitus | P3 | Completed | 833 | RCT, Double-blind | Dapagliflozin, Placebo for dapagliflozin |
| NCT00163358 Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132) | Asthma | P3 | Completed | 630 | RCT, Double-blind | Ciclesonide |
| NCT00163371 Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) | Asthma | P3 | Completed | 28 | RCT, Double-blind | Ciclesonide |
| NCT04053634 Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | Chronic Obstructive Pulmonary Disease | P3 | Completed | 689 | RCT, Double-blind | Benralizumab, Placebo |
| NCT00885378 Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P3 | Completed | 166 | RCT, Double-blind | Saxagliptin plus metformin IR, Placebo plus metformin IR |
| NCT00254813 Fast Titration Of Quetiapine Versus Currently Approved Titration | Psychotic Disorders | P3 | Completed | 150 | RCT, Open-label | Quetiapine |
| NCT05437510 Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life | RSV Immunization, Healthy Volunteer | P3 | Completed | 8,057 | RCT, Open-label | Nirsevimab |
| NCT04465968 Efficacy and Safety of CRT, Durvalumab and Surgery for SST | Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB | P3 | Not Yet Recruiting | 84 | Open-label | Cisplatin, S1, Durvalumab, Durvalumab |
| NCT01164540 Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis | Venous Thrombosis, Pulmonary Embolism | P3 | Withdrawn | 3,000 | RCT, Double-blind | Rosuvastatin (AZD4522), Placebo |
| NCT00399035 Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P3 | Completed | 1,254 | RCT, Double-blind | Cediranib, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), XELOX (Capecitabine and Oxaliplatin), Cediranib Placebo |
| NCT00676338 Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) | Type 2 Diabetes Mellitus | P3 | Completed | 820 | RCT, Double-blind | exenatide once weekly, metformin, sitagliptin, pioglitazone |
| NCT00666458 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D) | Type 2 Diabetes | P3 | Completed | 822 | RCT, Double-blind | saxagliptin, sitagliptin |
| NCT04625725 Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. | COVID-19 | P3 | Completed | 5,197 | RCT, Double-blind | AZD7442, Placebo |
| NCT00242294 Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06) | Chronic Obstructive Pulmonary Disease (COPD) | P2P3 | Completed | 570 | RCT, Double-blind | Roflumilast |
| NCT00241449 A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer | Breast Cancer, Metastasis | P3 | Completed | 51 | RCT, Double-blind | Fulvestrant, Tamoxifen |
| NCT02009865 Epanova® for Lowering Very High Triglycerides II (EVOLVE II) | Hypertriglyceridemia | P3 | Completed | 379 | RCT, Double-blind | Epanova, Olive Oil |
| NCT00667992 Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma | Asthma | P3 | Completed | 99 | RCT, Open-label | Budesonide HFA, Budesonide CFC |
| NCT00651547 Symbicort in Asthmatic Children - SEEDLING | Asthma | P3 | Completed | 405 | RCT, Double-blind | budesonide/formoterol, budesonide, formoterol |
| NCT01942135 Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | Metastatic Breast Cancer | P3 | Completed | 521 | RCT, Double-blind | Palbociclib, Fulvestrant, Placebo, Fulvestrant |
| NCT00595517 Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer | Gastric Ulcer, Duodenal Ulcer | P3 | Completed | 395 | Open-label | Esomeprazole 20 mg |
| NCT00463606 A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia | Hypercholesterolemia, Dyslipidemia | P3 | Completed | 760 | RCT, Double-blind | ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium |
| NCT00163449 Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207) | Asthma | P3 | Completed | 1,000 | RCT, Double-blind | Ciclesonide, Placebo |
| NCT01096017 To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study | Asthma | P3 | Completed | 24 | RCT, Single-blind | Terbutaline Turbuhaler®, Salbutamol pMDI |
| NCT04385368 Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | P3 | Completed | 89 | RCT, Double-blind | Durvalumab + SoC chemotherapy |
| NCT03706079 Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma | Asthma | P3 | Completed | 951 | RCT, Double-blind | Tezepelumab |
| NCT00575588 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period | Type 2 Diabetes | P3 | Completed | 891 | RCT, Double-blind | Metformin, Sulphonylurea, Saxagliptin |
| NCT02229396 Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo | Diabetes Mellitus | P3 | Completed | 695 | RCT, Double-blind | Exantide with Dapagliflozin, Exentide, Dapagliflozin |
| NCT00291759 ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation. | Breast Cancer | P3 | Completed | 3,858 | RCT, Open-label | Tamoxifen, Anastrozole |
| NCT02282020 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments | Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity | P3 | Completed | 266 | RCT, Open-label | OLAPARIB, Single agent chemotherapy |
| NCT00663260 Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment | Diabetes Mellitus, Type 2 | P2P3 | Completed | 631 | RCT, Double-blind | Dapagliflozin, Dapagliflozin, Placebo |
| NCT01395524 A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation | Opioid-Induced Constipation (OIC) | P3 | Completed | 302 | RCT, Double-blind | NKTR-118, NKTR-118, Placebo |
| NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. | Heart Failure With Preserved Ejection Fraction | P3 | Completed | 6,263 | RCT, Double-blind | Dapagliflozin, Placebo |
| NCT01646320 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes | Type 2 Diabetes | P3 | Completed | 320 | RCT, Double-blind | Dapagliflozin, Placebo matching with Dapagliflozin, Saxagliptin, Metformin immediate release (IR) |
| NCT00525824 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe | Hypercholesterolemia, Coronary Heart Disease | P3 | Completed | 1,743 | RCT, Open-label | Rosuvastatin (Crestor), Ezetimibe, Simvastatin |
| NCT00163488 Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409) | Perennial Allergic Rhinitis, Allergic Rhinitis | P3 | Completed | 106 | RCT, Double-blind | Ciclesonide |
| NCT00577824 Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Type 2 Diabetes | P3 | Completed | 181 | RCT, Double-blind | exenatide, exenatide, placebo |
| NCT03263091 Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden | Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia | P3 | Terminated | 184 | RCT, Double-blind | Roxadustat, Placebo |
| NCT00659841 To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401) | Rhinitis, Allergic, Seasonal, Hay Fever | P3 | Completed | 302 | RCT, Double-blind | Ciclesonide, Placebo |
| NCT00290264 SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma | Asthma | P3 | Completed | 1,000 | RCT, Open-label | Budesonide/formoterol |
| NCT02794285 Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus | Active Systemic Lupus Erythematosus | P3 | Completed | 559 | RCT, Double-blind | Anifrolumab, Placebo |
| NCT01003184 Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 222 | RCT, Open-label | exenatide once weekly, insulin detemir |
| NCT03608358 Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin | Type 2 Diabetes Mellitus | P3 | Terminated | 41 | RCT, Double-blind | Dapagliflozin 10 mg, Dapagliflozin 5 mg, Dapagliflozin 10 mg placebo to match, Dapagliflozin 5 mg placebo to match, Saxagliptin 5 mg, Metformin |
| NCT01757275 High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer | Bleeding Peptic Ulcer | P3 | Completed | 239 | RCT, Double-blind | Esomeprazole Na, Cimetidine, Esomeprazole Mg |
| NCT02670642 Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD | Gastroesophageal Reflux | P3 | Completed | 877 | RCT, Open-label | Esomeprazole |
| NCT00543127 Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | Breast Cancer | P3 | Terminated | 870 | RCT, Open-label | Fulvestrant, Anastrozole |
| NCT01838499 Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Terminated | 224 | RCT, Double-blind | MEDI8968, Saline |
| NCT00402896 Malignant Pleural Effusion With ZD6474 | Lung Cancer, Pleural Effusion | P2 | Terminated | 28 | Open-label | ZD6474 |
| NCT00672646 Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386 | Pain | P2 | Completed | 103 | RCT, Double-blind | AZD1386, Naproxen, Placebo |
| NCT05459688 Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 | Hypertension | P2 | Completed | 175 | Open-label | CIN-107 |
| NCT00103935 Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | P2 | Completed | 45 | RCT, Double-blind | placebo, placebo, Exenatide LAR, Exenatide LAR |
| NCT06419179 Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) | Small Cell Lung Carcinoma | P2 | By Invite | 29 | Open-label | Durvalumab, Olaparib |
| NCT02735239 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | Esophageal Cancer | P1P2 | Completed | 73 | Open-label | Durvalumab, Tremelimumab, Oxaliplatin, Capecitabine, Paclitaxel, Carboplatin, 5-fluorouracil (5-FU), Leucovorin, Docetaxel |
| NCT03205761 Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | Advanced Breast Cancer | P2 | Completed | 11 | Open-label | Olaparib |
| NCT00872716 Quetiapine in Specific Phobia | Specific Phobia | P2 | Completed | 60 | RCT, Double-blind | Quetiapine XR |
| NCT03563066 Effect of Benralizumab in Atopic Dermatitis | Dermatitis, Atopic, Dermatitis | P2 | Completed | 20 | RCT, Double-blind | Benralizumab, Placebo Control |
| NCT00338130 Randomised Study to Compare the Efficacy of AZD6244 vs TMZ | Melanoma | P2 | Completed | 239 | RCT, Open-label | AZD6244, Temozolomide |
| NCT00684307 Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation | Nonvalvular Atrial Fibrillation | P2 | Completed | 1,084 | RCT, Double-blind | AZD0837, Vitamin-K antagonist at INR 2-3, AZD0837 |
| NCT02822157 Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer | Ovarian Epithelial Cancer | P2 | Unknown | 160 | RCT, Open-label | Olaparib, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly |
| NCT00238628 A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | Lung Cancer | P1P2 | Completed | 6 | Open-label | Bexarotene, Iressa |
| NCT02597101 Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes | Type 2 Diabetes Mellitus, Insulin Resistance | P2 | Completed | 14 | RCT, Double-blind | Metformin, saxagliptin, AZD9668, placebo |
| NCT03394118 TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy | NSCLC | P2 | Completed | 63 | Open-label | Osimertinib |
| NCT00986479 This is a Study to Determine the Antidepressant Effects of AZD6765 | Treatment Resistant Major Depressive Disorder | P2 | Completed | 22 | RCT, Double-blind | AZD6765, Placebo to AZD6765 |
| NCT00514761 Phase II Efficacy Study of AZD6244 in Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Completed | 64 | RCT, Open-label | AZD6244, Capecitabine |
| NCT00635856 Open Label Trial to Assess Iressa in Prostate Cancer Patients | Prostate Cancer | P2 | Completed | 100 | Open-label | Gefitinib |
| NCT00099580 PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure | Congestive Heart Failure | P2 | Completed | 61 | RCT, Double-blind | AC2592, placebo |
| NCT02684318 Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | Advanced Cancer, Ovarian Cancer | P1P2 | Unknown | 100 | Open-label | PM01183 + olaparib |
| NCT01847092 A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria | Chronic Kidney Disease, Type 2 Diabetes Mellitus | P2 | Completed | 154 | RCT, Double-blind | AZD1722, Placebo |
| NCT00254579 Study of CP-675,206 in Refractory Melanoma | Refractory Melanoma | P2 | Completed | 251 | Open-label | CP-675,206 |
| NCT03871153 Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer | P2 | Terminated | 7 | Open-label | Paclitaxel, Carboplatin |
| NCT04644237 Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer | P2 | Completed | 152 | RCT, Double-blind | Trastuzumab deruxtecan |
| NCT01201317 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy | Neuropathic Pain | P2 | Completed | 134 | RCT, Double-blind | AZD2423, AZD2423, Placebo |
| NCT04230408 Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers | Lung Neoplasms | P2 | Completed | 48 | Open-label | Durvalumab |
| NCT04484935 Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children | RSV Infection | P2 | Completed | 100 | Open-label | Nirsevimab |
| NCT02450656 Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer | Colorectal Neoplasms, Gastrointestinal Neoplasms | P1P2 | Unknown | 320 | RCT, Open-label | Afatinib, Selumetinib, Docetaxel |
| NCT03235050 A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P2 | Completed | 834 | RCT, Double-blind | MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide |
| NCT00690482 Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Moderate to Severe COPD | P2 | Completed | 118 | RCT, Double-blind | AZD1981, Placebo |
| NCT00306891 Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™) | Cancer | P2 | Completed | 60 | RCT, Open-label | Cediranib, Cediranib 30 - 90 mg |
| NCT00303524 Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients | Breast Cancer | P2 | Completed | 170 | RCT, Open-label | Goserelin acetate, Goserelin acetate |
| NCT05383001 Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) | NSCLC Stage IV | P2 | Withdrawn | — | RCT, Open-label | combination regimen tremelimumab /durvalumab, platinum-based chemotherapy (SoC) |
| NCT00280865 GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes | Type 2 Diabetes | P2 | Completed | 500 | RCT, Double-blind | Tesaglitazar, Pioglitazone |
| NCT00242762 ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer | Head and Neck Cancer | P2 | Completed | 36 | Open-label | ZD1839 (IRESSA™), Docetaxel, Cisplatin |
| NCT00758459 Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients | Chronic Obstructive Pulmonary Disease | P2 | Completed | 74 | RCT, Double-blind | AZD1236, Placebo |
| NCT00298688 A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer | Small Cell Lung Cancer | P2 | Completed | 56 | Open-label | Gefitinib |
| NCT04262388 A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | P2 | Withdrawn | — | Open-label | Durvalumab, Oleclumab |
| NCT03782818 Olaparib for PAH: a Multicenter Clinical Trial | Pulmonary Arterial Hypertension | P1P2 | Terminated | 17 | Open-label | Olaparib |
| NCT03705507 International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult | P1P2 | Terminated | 12 | Open-label | Selumetinib, Dexamethasone |
| NCT04675034 A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee | Painful Osteoarthritis of the Knee | P2 | Completed | 345 | RCT, Double-blind | MEDI7352 |
| NCT06269484 A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK | Liver Cirrhosis | P2 | Completed | 73 | RCT, Double-blind | Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin |
| NCT03809663 A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 251 | RCT, Double-blind | Tezepelumab |
| NCT00402077 A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects | Overweight, Obesity | P2 | Completed | 258 | RCT, Single-blind | pramlintide acetate, sibutramine, phentermine, placebo |
| NCT00065572 Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV) | Carcinoma, Renal Cell, Kidney Neoplasms | P2 | SUSPENDED | — | RCT, Double-blind | ZD6126, Placebo |
| NCT03829007 PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC | Head and Neck Cancer | P1P2 | Completed | 33 | Open-label | Durvalumab |
| NCT06336356 A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension | Uncontrolled Hypertension | P2 | Completed | 48 | RCT, Double-blind | Baxdrostat, Placebo |
| NCT03337477 A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8 | Hyperkalemia | P2 | Completed | 70 | RCT, Double-blind | Placebo, Sodium Zirconium Cyclosilicate(ZS), Insulin, Glucose, Insulin, Glucose |
| NCT03579784 Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | Advanced Gastric Cancer | P2 | Unknown | 40 | Open-label | Paclitaxel, Olaparib, Durvalumab |
| NCT06179511 Study of AZD9829 in CD123+ Hematological Malignancies | Hematological Malignancies | P1P2 | Completed | 56 | Open-label | AZD9829, AZD9829 |
| NCT00193336 Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer | Lung Cancer | P2 | Completed | 60 | Open-label | ZD1839 |
| NCT01579578 Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer | Metastatic, Gastric or Gastro-oesophageal Junction, Cancer | P2 | Terminated | 39 | RCT, Double-blind | AZD8931, Placebo, Paclitaxel |
| NCT02901548 Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | Carcinoma in Situ of Bladder, Bladder Cancer | P2 | Terminated | 17 | Open-label | Durvalumab |
| NCT05375760 A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 | Coronavirus Disease 2019 (COVID-19) | P2 | Terminated | 251 | RCT, Open-label | AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]), AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) |
| NCT02879617 A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | Non-Small Cell Lung Cancer NSCLC | P2 | Completed | 47 | Open-label | durvalumab |
| NCT03432897 BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes | Prostate Cancer, Adenocarcinoma of the Prostate | P2 | Terminated | 1 | Open-label | Olaparib Pill |
| NCT01569074 Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 163 | RCT, Double-blind | Fostamatinib, Fostamatinib, Fostamatinib, Fostamatinib, Placebo |
| NCT00198393 Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 126 | RCT, Open-label | Gefitinib, gemcitabine, Docetaxel |
| NCT03177187 Combination Study of AZD5069 and Enzalutamide. | Metastatic Castration Resistant Prostate Cancer | P1P2 | Terminated | 30 | Open-label | AZD5069, Enzalutamide 40 MG |
| NCT00868231 Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients | Chronic Obstructive Pulmonary Disease (COPD) | P2 | Completed | 30 | RCT, Double-blind | Aclidinium bromide 400 μg bid, Tiotropium 18 μg once-daily, Placebo |
| NCT00239304 Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer | Head and Neck Neoplasms | P1P2 | Completed | 40 | Open-label | Gefitinib, Cisplatin |
| NCT01396226 A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients | Arrhythmia | P2 | Completed | 20 | RCT, Double-blind | AZD2927, Placebo |
| NCT03414814 Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation | Locally Advanced or Metastatic NSCLC | P2 | Completed | 15 | Open-label | Osimertinib 80 MG [Tagrisso] |
| NCT00054691 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | Skin Cancer | P2 | Completed | 40 | Open-label | Iressa |
| NCT00459043 Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck | Squamous Cell Carcinoma of Head and Neck | P2 | Completed | 30 | RCT, Open-label | ZD6474, Docetaxel |
| NCT03036891 Naloxegol for Opioid-Related Gastroparesis | Gastroparesis, Opioid Use | P2 | Withdrawn | — | RCT, Double-blind | Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet |
| NCT00659490 Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940 | Pain | P2 | Completed | 151 | RCT, Double-blind | AZD1940, Naproxen, Placebo |
| NCT01703260 Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis | Nonalcoholic Steatohapatitis | P2 | Terminated | 20 | RCT, Double-blind | Roflumilast, Pioglitazone, Placebo, Placebo |
| NCT00912743 Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status | Colorectal Cancer | P2 | Completed | 33 | Open-label | olaparib |
| NCT01136655 A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy | Asthma | P2 | Completed | 54 | RCT, Double-blind | 80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg, 40 μg budesonide HFA pMDI, placebo HFA pMDI |
| NCT00234403 A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 60 | Open-label | gefitinib and fulvestrant |
| NCT00296374 Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease | Diabetes Mellitus | P2 | Completed | 353 | RCT, Double-blind | Rosuvastatin, Rosuvastatin, Atorvastatin |
| NCT02311088 Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor | Dyspnea | P2 | Terminated | 26 | RCT, Double-blind | Caffeine, Placebo |
| NCT00687297 Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | Lung Cancer, Non Small Cell Lung Cancer | P2 | Completed | 162 | RCT, Double-blind | vandetanib induction, Docetaxel, Carboplatin, Placebo, Vandetanib maintenance |
| NCT02891161 Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | Urothelial Cancer | P1P2 | Terminated | 26 | Open-label | durvalumab |
| NCT03570476 Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8 | P2 | Terminated | 2 | Open-label | Olaparib |
| NCT04170543 A Phase 2b Diabetic Kidney Disease Study | Diabetic Kidney Disease | P2 | Completed | 609 | RCT, Double-blind | MEDI3506, Placebo, Dapagliflozin |
| NCT01043185 A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience | Gastroesophageal Reflux Disease | P2 | Completed | 27 | RCT, Double-blind | AZD3355, AZD3355, AZD3355, AZD3355, placebo |
| NCT00950599 Study of Multiple Doses of Saxagliptin (BMS-477118) | Type 2 Diabetes Mellitus | P2 | Completed | 423 | RCT, Double-blind | Saxagliptin, Saxagliptin, Saxagliptin, Saxagliptin, Saxagliptin, Saxagliptin, Placebo |
| NCT03522584 Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | P1P2 | Terminated | 6 | Open-label | Durvalumab, Tremelimumab |
| NCT02319044 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck | P2 | Completed | 267 | RCT, Open-label | MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab |
| NCT02482298 A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease | Sickle Cell Disease | P2 | Completed | 87 | RCT, Double-blind | Ticagrelor, Placebo |
| NCT00242749 IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma | Cancer of Head and Neck | P2 | Completed | 47 | Open-label | Gefitinib, Cisplatin and Radiotherapy |
| NCT00206245 A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis. | GERD With Erosive Esophagitis | P2 | Completed | 1,400 | RCT, Double-blind | AZD0865 |
| NCT03145194 TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI | ST Elevation Myocardial Infarction | P2 | Unknown | 140 | RCT, Double-blind | Ticagrelor |
| NCT04327024 Study of Verinurad in Heart Failure With Preserved Ejection Fraction | Heart Failure With Preserved Ejection Fraction (HFpEF) | P2 | Completed | 159 | RCT, Double-blind | Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol |
| NCT03234153 Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin | Muscle-invasive Bladder Cancer | P2 | Terminated | 6 | Open-label | Durvalumab (Imfinzi), Tremelimumab |
| NCT01904773 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder | Tourette Syndrome | P2 | Completed | 29 | RCT, Double-blind | AZD5213 and placebo |
| NCT01065662 AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | Endometrial Cancer, Ovarian Cancer | P1 | Completed | 11 | Open-label | temsirolimus, cediranib |
| NCT00899470 Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A) | Type 2 Diabetes Mellitus | P1 | Completed | 24 | RCT, Open-label | Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed |
| NCT00738842 Uric Acid Study in Healthy Male Volunteers | Gout, Coronary Artery Disease | P1 | Completed | 24 | RCT, Double-blind | AZD6140, Placebo to match AZD6140 |
| NCT03273127 To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids | Asthma | P1 | Completed | 12 | RCT, Single-blind | Abediterol, Placebo |
| NCT06715670 A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants | Liver Cirrhosis | P1 | Completed | 30 | RCT, Open-label | Zibotentan |
| NCT05419401 A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) | Healthy Volunteer | P1 | Completed | 7 | Open-label | Capivasertib film-coated tablet, 200 mg, [14C]AZD5363 (Capivasertib) |
| NCT02588105 Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | Advanced Solid Tumours | P1 | Completed | 84 | Open-label | AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid |
| NCT00799331 Exploratory Study to Assess the Pharmacokinetics of AZD5985 | Healthy | P1 | Completed | 32 | RCT, Double-blind | AZD5985, placebo |
| NCT06754761 Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib | Neoplasm | P1 | Terminated | 2 | Open-label | [14C] AZD6738, AZD6738 / ceralasertib |
| NCT02585973 Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | Carcinoma, Squamous Cell of Head and Neck | P1 | Completed | 12 | Open-label | AZD1775, Cisplatin |
| NCT06675175 A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. | Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease | P1 | Completed | 29 | RCT, Double-blind | AZD4144 |
| NCT01146756 MEK Inhibitor and Thoracic Radiotherapy Trial | Non Small Cell Lung Cancer | P1 | Completed | 21 | Open-label | AZD6244 |
| NCT00720421 A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator. | Healthy Volunteer | P1 | Completed | 16 | RCT, Double-blind | AZD7325, AZD7325, AZD7325, Lorazepam, Lorazepam |
| NCT02317016 Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | Non Small Cell Lung Cancer | P1 | Completed | 44 | Open-label | AZD9291 tablet dosing, Rosuvastatin |
| NCT04256629 A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart | Healthy Volunteers (Intended Indication: Chronic Kidney Disease) | P1 | Completed | 24 | RCT, Double-blind | Verinurad, Placebo, Allopurinol |
| NCT02308072 Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer | Head and Neck Cancer | P1 | Completed | 16 | Open-label | Olaparib, Cisplatin |
| NCT02718911 A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 72 | Open-label | LY3022855, Durvalumab, Tremelimumab |
| NCT01083212 To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656 | Type 2 Diabetes Mellitus | P1 | Completed | 19 | RCT, Open-label | AZD1656, Gemfibrozil, Placebo |
| NCT01500018 Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214 | Drug Abuse, Healthy | P1 | Withdrawn | — | RCT, Double-blind | TC-5214, TC-5214 Placebo, Ketamine, Phentermine, TC-5214, TC-5214, Phentermine |
| NCT05110976 A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists | Asthma | P1 | Completed | 170 | RCT, Double-blind | AZD8630, Placebo |
| NCT00844324 Bioequivalence Study in Healthy Subjects | Hypertension | P1 | Completed | 36 | RCT, Open-label | Candesartan cilexetil, Candesartan cilexetil |
| NCT00497679 AZD1152 in Patients With Advanced Solid Malignancies-Study 3 | Solid Tumours | P1 | Terminated | 45 | Open-label | AZD1152 |
| NCT01664624 Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes | Type 2 Diabetes | P1 | Completed | 40 | RCT, Double-blind | Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin |
| NCT02093351 To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | Solid Tumours | P1 | Completed | 79 | Open-label | Olaparib, Tamoxifen, Anastrozole, Letrozole |
| NCT03804645 A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects | Heart Failure | P1 | Completed | 12 | RCT, Open-label | Treatment A, Treatment B, Treatment C, Treatment D |
| NCT03649165 A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants | P1 | Completed | 24 | RCT, Open-label | Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen |
| NCT00986531 The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics | Schizophrenia | P1 | Completed | 59 | RCT, Double-blind | AZD8529, Placebo to match AZD8529 |
| NCT01358383 Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers | Juvenile Idiopathic Arthritis | P1 | Completed | 28 | Open-label | naproxen, esomeprazole |
| NCT01403922 To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension | Chronic Hypertension | P1 | Terminated | 80 | RCT, Double-blind | TC-5214, TC-5214 |
| NCT02484729 A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males | Safety, Tolerability | P1 | Completed | 196 | RCT, Single-blind | AZD9977, oral suspension, Placebo, oral suspension, AZD9977, oral solution |
| NCT00901290 Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects | Pharmacokinetics | P1 | SUSPENDED | 56 | RCT, Double-blind | monophasic oral contraceptive, AZD7325 |
| NCT01562210 Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC | NSCLC | P1 | Completed | 28 | Open-label | Olaparib, Cisplatin |
| NCT00858325 Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China | Healthy | P1 | Completed | 24 | Open-label | Daptomycin |
| NCT05438303 Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers | Healthy Volunteers | P1 | Completed | 59 | RCT, Open-label | AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib |
| NCT01744288 Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets | Inhibition on Platelet Aggregation | P1 | Completed | 258 | RCT, Open-label | Ticagrelor, Clopidogrel, ASA |
| NCT03368196 DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | Adenocarcinoma, Gastric, Neoplasm, Breast | P1 | Completed | 12 | Open-label | DS-8201a |
| NCT02934607 A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers | Study is Being Conducted in Healthy Volunteers | P1 | Completed | 50 | RCT, Open-label | Symbicort pMDI with spacer device, Symbicort pMDI without spacer device |
| NCT05963009 Baxdrostat Bioavailability and Bioequivalence Study | Hypertension | P1 | Completed | 14 | RCT, Open-label | baxdrostat (formerly CIN-107) oral solution |
| NCT00967356 AZD5985 Single Ascending Dose Study | Healthy | P1 | Terminated | 72 | RCT, Double-blind | AZD5985, Placebo |
| NCT02010970 A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate | Healthy Volunteers, Pharmacologic Action | P1 | Completed | 56 | Open-label | Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam |
| NCT01034982 AZD9668 Relative Bioavailability | Chronic Obstructive Pulmonary Disease | P1 | Completed | 28 | RCT, Open-label | AZD9668, AZD9668 |
| NCT01469923 To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses | Obesity | P1 | Terminated | 18 | RCT, Single-blind | AZD2820, Placebo |
| NCT01355354 Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects | Healthy Volunteers, Rheumatoid Arthritis | P1 | Completed | 21 | Open-label | Digoxin, Fostamatinib |
| NCT00904176 Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects | Type 2 Diabetes Mellitus | P1 | Completed | 30 | RCT, Open-label | Dapagliflozin, Warfarin, Digoxin |
| NCT01392807 Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function | Hepatic; Functional Disturbance | P1 | Completed | 24 | Open-label | NKTR-118 |
| NCT00687232 Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers | Healthy | P1 | Completed | 30 | RCT, Single-blind | AZD4818, Placebo |
| NCT00667147 Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib | Solid Tumors | P1 | Completed | 65 | RCT, Open-label | Weekly Abraxane and Daily Vandetanib, Abraxane every three weeks and daily vandetanib |
| NCT01739647 A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects | Healthy Young Volunteers, Healthy Elderly Volunteers | P1 | Completed | 72 | RCT, Double-blind | AZD3293, Placebo |
| NCT07500987 Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC | EGFR Mutation-positive NSCLC | P1 | Terminated | 6 | Open-label | [111In]-FPI-2107, FPI-2053 |
| NCT00689039 Study of an Extended Release (ER) Tablet, Single and Repeated Dosing | Healthy | P1 | Completed | 94 | RCT, Single-blind | AZD1305, Placebo |
| NCT00770302 Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin | Type 2 Diabetes | P1 | Completed | 34 | Open-label | Saxagliptin |
| NCT02400333 Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet | Bioavailability, Healthy Subjects | P1 | Completed | 100 | RCT, Open-label | Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube, Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water |
| NCT02063204 To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects | Solid Tumours | P1 | Completed | 24 | Open-label | selumetinib |
| NCT03545087 A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants | Renal Insufficiency | P1 | Withdrawn | — | Open-label | Lanabecestat, Iohexol |
| NCT05587998 A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users. | Opioid Use Disorder | P1 | Completed | 45 | RCT, Double-blind | Morphine, AZD4041 |
| NCT04449484 Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease | Parkinson's Disease | P1 | Completed | 25 | RCT, Double-blind | MEDI1341 |
| NCT05166421 Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants | Corona Virus Disease | P1 | Completed | 224 | RCT, Open-label | AZD7442, AZD8895 (clonal cell line material), AZD1061 (clonal cell line material), AZD8895 (cell pool material), AZD1061 (cell pool material) |
| NCT00920608 A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | P1 | Withdrawn | 12 | Open-label | AZD9056, Methotrexate |
| NCT02508155 A Study of MEDI7352 in Painful Osteoarthritis of the Knee | Chronic Pain | P1 | Completed | 132 | RCT, Double-blind | MEDI7352 for IV infusion, Placebo for IV infusion, MEDI7352 for Subcutaneous Injection, Placebo for Subcutaneous Injection |
| NCT01525225 Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM | Type 2 Diabetes Mellitus | P1 | Terminated | 4 | Open-label | Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR |
| NCT04073160 TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer | Bladder Cancer | P1 | Withdrawn | — | Open-label | Tremelimumab, Durvalumab, Intravesicular Therapy |
| NCT05236543 A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole | Healthy Volunteers | P1 | Completed | 21 | Open-label | AZD4831, Itraconazole |
| NCT00785915 AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects | Healthy | P1 | Completed | 40 | RCT, Double-blind | AZD6765, Placebo |
| NCT07069725 The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. | Liver Fibrosis, Hepatic Cirrhosis | P1 | Completed | 8 | Open-label | AZD2389 |
| NCT01226602 Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects. | Blood Flow Speed, Coronary Flow Velocity | P1 | Completed | 39 | RCT, Double-blind | AZD6140, Placebo |
| NCT00712465 An Interaction Study With Digoxin and AZD1305 | Atrial Fibrillation | P1 | Completed | 18 | RCT, Open-label | AZD1305, Digoxin |
| NCT01839604 A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma, Hepatocellular Carcinoma Metastatic | P1 | Completed | 58 | Open-label | AZD9150 |
| NCT00866385 AZD8566 Food Effect/Microtracer Study | Healthy Volunteer Study | P1 | Completed | 21 | RCT, Open-label | AZD8566, AZD8566 IV carbon labelled |
| NCT00973076 Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 | Cancer, Solid Tumors | P1 | Completed | 19 | Open-label | AZD8055 |
| NCT03635164 Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck | P1 | Completed | 21 | Open-label | Durvalumab |
| NCT05848843 A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Lung Cancer, Gastro-intestinal Cancer | P1 | Withdrawn | — | RCT, Open-label | Durvalumab, Adagrasib |
| NCT01783197 Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | Non Small Cell Lung Cancer | P1 | Completed | 39 | Open-label | Paclitaxel, Carboplatin, Selumetinib, Pemetrexed, Cisplatin |
| NCT00600496 A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | Breast Cancer, Breast Neoplasms | P1 | Completed | 140 | Open-label | AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus |
| NCT05457270 A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers. | Healthy Volunteers | P1 | Completed | 30 | RCT, Open-label | AZD4831 |
| NCT01030224 This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects | Healthy | P1 | Completed | 48 | RCT, Double-blind | AZD9742, Placebo to match AZD9742 |
| NCT00681720 Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 | Anxiety | P1 | Completed | 4 | Open-label | AZD7325, Radioligand (11C) flumazenil |
| NCT02039180 Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects | Healthy Volunteers, Pharmacologic Action | P1 | Completed | 1 | RCT, Open-label | AZD3293 oral solution, AZD3293 tablet formulation A, AZD3293 tablet formulation B |
| NCT00930215 Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males | Healthy | P1 | Completed | 48 | RCT, Open-label | D961H, D961H |
| NCT05848440 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants | Non-alcoholic Steatohepatitis | P1 | Completed | 48 | RCT, Double-blind | AZD9550, AZD9550, Placebo |
| NCT01264250 A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers | Healthy | P1 | Completed | 48 | RCT, Double-blind | AZD2927, Placebo |
| NCT00497991 Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia | Myeloid Leukemia | P1 | Completed | 65 | Open-label | AZD1152 |
| NCT02346890 A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722 | Healthy | P1 | Completed | 16 | RCT, Open-label | AZD1722, Renvela |
| NCT01809210 Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer | Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV | P1 | Completed | 55 | Open-label | selumetinib, gemcitabine, cisplatin, carboplatin, pemetrexed |
| NCT04994106 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers | Healthy Participants | P1 | Completed | 98 | RCT, Double-blind | AZD5462, Placebo |
| NCT06795906 A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma | Asthma | P1 | Completed | 24 | Double-blind | AZD8630 |
| NCT02968914 Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers | Asthma, Chronic Obstructive Pulmonary Disease | P1 | Completed | 180 | RCT, Open-label | Benralizumab, Benralizumab |
| NCT06651021 A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants | Healthy Volunteer | P1 | Completed | 10 | Open-label | balcinrenone/dapagliflozin |
| NCT01160926 Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial | Rectal Cancer | P1 | Terminated | 31 | Open-label | AZD6244, Cediranib (AZD2171) |
| NCT07423598 A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels | Healthy Participants | P1 | Completed | 40 | RCT, Double-blind | AZD0780, Placebo |
| NCT00790114 Determine the Effect of Multiple Doses of AZD7325, CYP Study | Healthy Volunteer | P1 | Completed | 24 | RCT, Double-blind | AZD7325, Midazolam, Caffeine |
| NCT05662033 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State. | Inflammatory Diseases | P1 | Completed | 93 | RCT, Single-blind | AZD6793, Placebo |
| NCT00389389 Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors | Neoplasms | P1 | Completed | 75 | Open-label | AZD4877 |
| NCT03588546 FASENRA SCEI for Long-term Use | Asthma | Completed | 653 | — | — | |
| NCT00770250 National Survey on Asthma | Asthma | Completed | 1,704 | — | — | |
| NCT03131362 Realize the Current Situation of COPD Patients in China | Chronic Obstructive Pulmonary Disease COPD | Completed | 5,020 | — | — | |
| NCT02316990 China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients | Stress Ulcers, Stress-related Mucosal Disease (SRMD) | Completed | 1,416 | — | — | |
| NCT01160679 Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia | Schizophrenia | Completed | 231 | — | — | |
| NCT01208779 Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer | Hormon Receptor Positive Breast Cancer | Completed | 90 | — | — | |
| NCT05020717 Retrospective Survey of Hyperkalemia in Hemodialysis | Hemodialysis Complication | Unknown | 300 | — | — | |
| NCT06455462 Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres | Severe Asthma | Completed | 352 | — | Tezepelumab | |
| NCT01130961 Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand | Lung Cancer | Completed | 104 | — | — | |
| NCT01275794 Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage | Type 2 Diabetes | Completed | 1,849 | — | — | |
| NCT02226822 DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan | Type 2 Diabetes Mellitus | Completed | 1,869 | — | — | |
| NCT06321731 Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain. | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 718 | — | — | |
| NCT00928629 Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease | Peripheral Arterial Disease | N/A | Completed | 1,000 | Open-label | — |
| NCT05548777 Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed | Anticoagulant-related Major Bleed | Completed | 5,480 | — | Andexanet alfa, 4F-PCC | |
| NCT00681837 Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France | Gastroesophageal Reflux | Completed | 2,500 | — | — | |
| NCT00785057 Retrospective Treatment Pattern Survey for the Patient With and Without History of Stroke | Hypertension | Completed | 1,000 | — | — | |
| NCT00233584 Pulmicort Asthma Prevention (Post-PAC) | Asthma | N/A | Completed | 400 | Open-label | — |
| NCT02695121 Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment | Breast Cancer, Bladder Cancer | Completed | 2,133,575 | — | — | |
| NCT07103629 Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap | Renal Insufficiency, Chronic | Completed | 8,428 | — | — | |
| NCT06614712 OPTIMISE-CKD Study_current Clinical Landscape in Spain | Renal Disease | Completed | 91,628 | — | — | |
| NCT05932901 OPTIMISE-CKD Drug Utilization | Chronic Kidney Disease | Completed | 2,682,052 | — | — | |
| NCT00699959 National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups | Coronary Patients, Heart Failure | Completed | 1,650 | — | — | |
| NCT05180396 A Study on Disease Awareness and Treatment Compliance of Heart Failure Patients | Heart Failure | Completed | 200 | — | — | |
| NCT01164397 Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients | Dyslipidemia | Completed | 268 | — | — | |
| NCT01944618 forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP) | Type 2 Diabetes | Terminated | 5,000 | — | Forxiga | |
| NCT06131424 NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients | HER2-negative | Completed | 1,151 | — | — | |
| NCT00680082 Observational Usage Study of Statins in Primary Care in France | Healthy | Completed | 2,100 | — | — | |
| NCT04901260 AMAZE™ Asthma Implementation QI Study | Asthma | Completed | 117 | — | — | |
| NCT04391283 First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting | Carcinoma, Non-Small-Cell Lung | Unknown | 500 | — | Osimertinib | |
| NCT03258788 A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | Completed | 15 | — | — | |
| NCT04696692 Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma | N/A | Completed | 60 | Open-label | — |
| NCT00882336 European Study of Cardiovascular Risk | Cardiovascular Risk Factors, Hyperlipidemia | Completed | 7,200 | — | — | |
| NCT00692874 Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy | Prostate Cancer | Completed | 1,646 | — | — | |
| NCT01292018 Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India | Dyslipidemia, Type 2 Diabetes Mellitus | Completed | 5,400 | — | — | |
| NCT01199536 Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers | Duodenal Ulcer | Completed | 59 | — | — | |
| NCT02733601 Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria | Oncology, Epidemiology | Completed | 1,500 | — | — | |
| NCT04878237 Kinetics of Nasal Cytokine Responses to Mechanical Stimulation | Allergic Rhinitis Due to Grass Pollen, Allergic Asthma | N/A | Completed | 30 | Open-label | — |
| NCT05663957 eVusheld Assessment reaL wORld Effectiveness in the VA Health System | SARS-CoV-2, COVID-19 | Completed | 5,814 | — | Evusheld | |
| NCT00913731 Quality Project to Evaluate and Validate the FAST-O Rating Scale | Acute Psychotic Symptoms | Completed | 111 | — | — | |
| NCT04884269 A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab | Carcinoma, Non-Small-Cell Lung | Completed | 144 | — | — | |
| NCT03721289 Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients | Carcinoma, Non-Small-Cell Lung | Completed | 463 | — | — | |
| NCT00434460 Study of Knowledge Translation of Clinical Practice Guidelines for Ventilator Associated Pneumonia | Ventilator Associated Pneumonia | Completed | 1,320 | — | — | |
| NCT00533260 A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine) | Bipolar Disorder, Schizophrenia | Completed | 128 | — | — | |
| NCT03798535 First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy | NSCLC | Completed | 1,156 | — | — | |
| NCT03038789 XIGDUO Extended Release (XR) Post Marketing Surveillance | Adult Patients With Type 2 Diabetes Mellitus | Completed | 623 | — | — | |
| NCT01202617 Seroquel XR in the Long Term Treatment of Schizophrenia | Relapse in Schizophrenia | Completed | 1,606 | — | — | |
| NCT07764835 Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) | Hepatocellular Carcinoma, Liver Cirrhosis | Not Yet Recruiting | 300 | — | — | |
| NCT02695095 Acute Liver Injury in Patients on Dapagliflozin | Acute Liver Injury | Completed | 424,091 | — | — | |
| NCT01106781 A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology | Non-Small Cell Lung Cancer | Completed | 591 | — | — | |
| NCT05826366 Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI | Carcinoma, Non-Small-Cell Lung | Completed | 296 | — | — | |
| NCT02962492 An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes | Evaluate Ketogenic Stress | N/A | Completed | 70 | RCT, Double-blind | Exenatide/Exenatide extended release, Dapagliflozin, Placebo |
| NCT03137264 Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients | Non-small Cell Lung Cancer | Completed | 44 | — | Other | |
| NCT01110564 Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease | Chronic Obstructive Pulmonary Disease | Completed | 515 | — | — | |
| NCT01298739 Asthma Control Study 2011 | Asthma Control Level | Completed | 1,524 | — | — | |
| NCT06676436 Observational Study on the Treatment of Patients With Metastatic Breast Cancer | Cancer | Completed | 204 | — | — | |
| NCT00880711 Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC) | Breast Cancer | Completed | 57 | — | — | |
| NCT01921127 Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients | COPD | Completed | 3,000 | — | — | |
| NCT07392710 Clinical Evaluation of the Nova Max Pro StatSensor Device | Kidney Transplant, Kidney Disease, Chronic | N/A | Completed | 100 | Open-label | — |
| NCT02305680 Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension | Acute Coronary Syndromes | Completed | 2,334 | — | — | |
| NCT07103642 EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study) | Pulmonary Disease, Chronic Obstructive | Completed | 3,402 | — | BGF | |
| NCT00696527 National Survey on Infiltrative Breast Cancer | Infiltrative Breast Cancer | Completed | 1,500 | — | — | |
| NCT03642613 The Study for Evaluating Factors Relating to Daily Step Counts and Physical Activity in Japanese Patients With COPD. | Pulmonary Disease, Chronic Obstructive | Completed | 505 | — | — | |
| NCT06514144 Exacerbations Among Patients Receiving Breztri (EROS Study) | Pulmonary Disease, Chronic Obstructive | Completed | 2,409 | — | BGF | |
| NCT02506816 Preoperative Olaparib Endometrial Carcinoma Study (POLEN) | Endometrial Carcinoma | Completed | 36 | — | Olaparib | |
| NCT02955316 Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China | Irritable Bowel Syndrome (IBS) | Completed | 3,000 | — | — | |
| NCT01776684 Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis | EGFR Mutation Positive Non-small Cell Lung Cancer | N/A | Unknown | 200 | Open-label | EGFR TKIs (gefitinib, erlotinib, afatinib, et al) |
| NCT00879736 A Study of the Effect of Patient Education (Talking Health Together) in Improving Doctor-patient Communication | Doctor-patient Communication Improvement | N/A | Completed | 322 | RCT, Single-blind | — |
| NCT06998095 Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea | Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP) | Not Yet Recruiting | 210 | — | — | |
| NCT01678339 Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients | Acute Coronary Syndrome, Acute Myocardial Infarction | Withdrawn | — | — | — | |
| NCT04149067 Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain | Diabetes Mellitus, Type 2 | Completed | 1,080 | — | Dapagliflozin, Sitagliptin | |
| NCT00946452 Symbicort SMART Satisfaction From Patient Perspective 2009 | Asthma | Completed | 205 | — | — | |
| NCT00683306 Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | Non Small Cell Lung Cancer (NSCLC) | APPROVED_FOR_MARKETING | — | — | ZD1839 (Iressa) | |
| NCT00689455 Regional Observatory on Metabolic Syndrome- LAZIO | Metabolic Syndrome | Completed | 1,574 | — | — | |
| NCT01194843 Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations | Hepatectomy, Pain | N/A | Completed | 85 | RCT, Double-blind | Ropivacaine, Physiological serum |
| NCT04928417 Exacerbations and Their Outcomes International (EXACOS International) | Chronic Obstructive Pulmonary Disease | Completed | 1,762 | — | — | |
| NCT00638391 Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer | Breast Cancer | Completed | 1,600 | — | Anastrozole | |
| NCT03375450 Treatment and Exacerbation in COPD Subjects | Comparative Effectiveness Study | Completed | 60,243 | — | — | |
| NCT02459990 Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom | Hypertension | Completed | 22,000 | — | — | |
| NCT05950997 A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL | Chronic Lymphocytic Leukemia | N/A | Unknown | 89 | Open-label | Acalabrutinib, Obinutuzumab |
| NCT00944489 To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension | Hypertension | Completed | 1,150 | — | — | |
| NCT06056778 The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA) | Systemic Lupus Erythematosus | Completed | 628 | — | — | |
| NCT00738725 BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population | Plaque, Atherosclerotic Disease | Completed | 7,687 | — | — | |
| NCT01767974 Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer | Non-Small Cell Lung Cancer | Unknown | 140 | — | — | |
| NCT07674121 PROLONG (PRostateOLaparibONcombinationGcc) Study | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Not Yet Recruiting | 75 | — | Olaparib and Abiraterone Combination | |
| NCT01185314 To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer | N/A | Completed | 1,270 | Open-label | — |
| NCT02234973 Transformation of Indigenous Primary Healthcare Delivery | Type 2 Diabetes Mellitus | Completed | 500 | — | — | |
| NCT02990117 ICS Treatment Compliance of Asthma Patients | Asthma, Allergic | Completed | 350 | — | — | |
| NCT05461378 PREP (Pre-Exposure Prophylaxis) of COVID-19 | Immuno-Deficiency, COVID-19 | Completed | 138 | — | Evusheld | |
| NCT00681707 Retrospective Treatment Pattern Survey for the Patients With Hypertension and Stroke | Hypertension | Completed | 1,000 | — | — | |
| NCT01694758 OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA | Diabetes Mellitus, Non-Insulin-Dependent | Completed | 733 | — | — | |
| NCT01814943 The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users | Uncomplicated Peptic Ulcer | Completed | 39,000 | — | — | |
| NCT03212287 Brilinta Clinical Experience Investigation | Acute Coronary Syndrome, Old Myocardial Infarction | Completed | 663 | — | — | |
| NCT00970918 Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs | Cardiovascular Disease | N/A | Completed | 2,609 | — | Blood sample testing for hs-CRP |
| NCT00842387 Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD) | Reflux, Heartburn | Completed | 2,370 | — | — | |
| NCT03517917 Prospective Tissue Collection Research Protocol | Solid Tumor | Completed | 221 | — | — | |
| NCT07800858 Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism | Primary Aldosteronism | N/A | Not Yet Recruiting | 30 | Open-label | baxdrostat |
| NCT06073574 CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | Completed | 160 | — | — | |
| NCT00523679 Symbicort SMART (Symbicort Maintenance And Reliever Therapy) | Asthma | Completed | 2,000 | — | — | |
| NCT04125290 US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) | Hairy Cell Leukemia | Terminated | 2 | — | — | |
| NCT00320970 Angiotensin II Antagonism of TGF-Beta 1 | Diabetic Nephropathy, Hypertension | N/A | Completed | 36 | Open-label | Candesartan |
| NCT04207203 Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study | Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5 | N/A | Completed | 26 | Open-label | — |
| NCT00916513 Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey | Diabetes | Completed | 5,926 | — | — | |
| NCT05712096 eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services | SARS-CoV-2, COVID-19 | Completed | 4,000 | — | EVUSHELD | |
| NCT01874262 A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction | Myocardial Infarction | N/A | Completed | 174 | RCT, Open-label | — |
| NCT02805361 Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus | Type II Diabetes Mellitus | Completed | 511 | — | — | |
| NCT02695082 Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications | Acute Kidney Injury | Completed | 539,310 | — | — | |
| NCT01395550 Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event | Cardiovascular Events | Completed | 88 | — | — | |
| NCT06039683 A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region | Carcinoma, Non-Small-Cell Lung | Completed | 54 | — | — | |
| NCT01917643 Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients | COPD Exacerbation | Completed | 2,396 | — | — | |
| NCT06365593 hATTR Polyneuropathy in Russia | Hereditary Transthyretin Amyloidosis | Completed | 100 | — | — | |
| NCT01338363 Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists | Hospitalized Cases of Angioneurotic Oedema, Pneumonia | Completed | 23,470 | — | — | |
| NCT01781416 Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk | Cardiovascular Risk | Completed | 799 | — | — | |
| NCT01426893 Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct | Asthma,, Chronic Obstructive Pulmonary Disease | Completed | 310 | — | — | |
| NCT05532995 Responses to CPET in Subjects With Persistent Exercise Intolerance After COVID-19: an Open-Source Exercise Network | COVID-19 | Completed | 1,200 | — | — | |
| NCT00597168 Quality of Life in Schizophrenic Patients | Schizophrenia | Completed | 124 | — | — | |
| NCT00900861 Asthma Control and Clinical Practice in Hungary 2009 | Asthma Control Level | Completed | 3,000 | — | — | |
| NCT05774431 Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry | Acute Myocardial Infarction | Completed | 6,789 | — | — | |
| NCT04105153 Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC | EGFR Positive Non-small Cell Lung Cancer | Completed | 400 | — | — | |
| NCT00984373 Epidemiology of Schizophrenia in Bulgaria | Schizophrenia | Completed | 440 | — | — |